- Updated results from the Phase 3 CheckMate-214 study evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in patients with previously untreated advanced/metastatic renal cell carcinoma (RCC) continued to show a survival benefit compared to Pfizer 's (NYSE:PFE) Sutent (sunitinib). The data will be presented at the ASCO GU Cancers Symposium in San Francisco.
- At month 30, overall survival (OS) in the intermediate- and poor-risk population was 60% in the Opdivo/Yervoy group compared to 47% in the Sutent group with 34% less risk of death (hazard ratio = 0.66).
- The overall response rate (ORR) also favored Opdivo/Yervoy, 42% vs. 29% (p=0.0001). 52% of intermediate- and poor-risk patients who responded experienced a durable response of at least 18 months compared to 28% for Sutent.
- The complete response rate in the Opdivo/Yervoy cohort was 11% compared to 1% for Sutent.
- Now read: A Special Situation Set Up By Bristol-Myers Squibb's Offer For Celgene (NASDAQ:CELG)
Original article